Literature DB >> 18067627

Management of field change in actinic keratosis.

M Vatve1, J-P Ortonne, M A Birch-Machin, G Gupta.   

Abstract

Field cancerization was first described in 1953 as histologically altered mucosa surrounding tumours removed from the upper gastro-intestinal tract. Over the years the definition has changed to include an area which is clinically occult but has multifocal preneoplastic changes, showing genetic mutations and which precedes the development of second primary tumours and local recurrences. Field cancerization has been described in the oropharynx, oesophagus, stomach, lung, colon, anus, cervix, bladder and skin. Various molecular techniques have been developed to look for genetic mutations and clonality in areas of field change. These studies have highlighted the need for early detection and treatment in order to prevent the development of tumours and local recurrences. In this article we examine the concept of field cancerization and treatments available to manage field change.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18067627     DOI: 10.1111/j.1365-2133.2007.08268.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  15 in total

1.  Long-term Follow up of Diclofenac Sodium 3% in 2.5% Hyaluronic Acid Gel for Actinic Keratosis: One-year Evaluation.

Authors:  Christopher Nelson; Darrell Rigel
Journal:  J Clin Aesthet Dermatol       Date:  2009-07

2.  Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach.

Authors:  James Q Del Rosso; Leon Kircik; Gary Goldenberg; Berman Brian
Journal:  J Clin Aesthet Dermatol       Date:  2014-09

3.  Trends in the Access and Cost of Photodynamic Therapy Among Medicare Beneficiaries in the United States, 2012-2017.

Authors:  Shayan Cheraghlou; Hao Feng; Jeffrey M Cohen
Journal:  JAMA Dermatol       Date:  2020-09-01       Impact factor: 10.282

Review 4.  Interventions for actinic keratoses.

Authors:  Aditya K Gupta; Maryse Paquet; Elmer Villanueva; William Brintnell
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 5.  An evolutionary perspective on field cancerization.

Authors:  Kit Curtius; Nicholas A Wright; Trevor A Graham
Journal:  Nat Rev Cancer       Date:  2017-12-08       Impact factor: 60.716

6.  Three-day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: A Phase II Trial.

Authors:  Daniel M Siegel; Stephen Tyring; Walter K Nahm; Marie Louise Østerdal; Astrid H Petersen; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2017-12-01

7.  Noninvasive Long-term Monitoring of Actinic Keratosis and Field Cancerization Following Treatment with Ingenol Mebutate Gel 0.015.

Authors:  Orit Markowitz; Katie Wang; Amanda Levine; Michelle Schwartz; Sumeet Minhas; Eleanor Feldman; Daniel M Siegel
Journal:  J Clin Aesthet Dermatol       Date:  2017-10-01

8.  Diclofenac gel in the treatment of actinic keratoses.

Authors:  Christopher G Nelson
Journal:  Ther Clin Risk Manag       Date:  2011-06-15       Impact factor: 2.423

9.  Reduced P53 Staining in Actinic Keratosis is Associated with Squamous Cell Carcinoma: A Preliminary Study.

Authors:  Pimentel Dr Neto; Mma Alchorne; Ns Michalany; Mamm Abreu; Rc Borra
Journal:  Indian J Dermatol       Date:  2013-07       Impact factor: 1.494

10.  Whales use distinct strategies to counteract solar ultraviolet radiation.

Authors:  Laura M Martinez-Levasseur; Mark A Birch-Machin; Amy Bowman; Diane Gendron; Elizabeth Weatherhead; Robert J Knell; Karina Acevedo-Whitehouse
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.